Association of FADS2 polymorphism rs174538 with fatty acid metabolism and disease severity in Japanese patients with Crohn’s disease

Table 1 Clinical data for study subjects, n (%)

Variable	Value
Age, years, median (min-max)	33.4 ± 13.2 (18-73)
Female	15 (28.8)
BMI, median (min-max)	21.0 (14.9-31.6)
Disease location
Ileum-colon type	36 (69.2)
Ileum type	9 (17.3)
Colon type	7 (13.5)
Disease duration, year
< 1	13 (25.0)
1-3	11 (21.2)
> 3	28 (53.8)
Medications, n
TNF-α inhibitor	30 (IFX: 17, ADA: 13)
Azathioprine	17
Aminosalicylate	51
Corticosteroids	1
CDAI, median ± SD	114.9 ± 90.6
Surgery	15 (28.8)
Endoscopic activity
Remission	10 (19.2)
Mild	13 (25.0)
Moderate	18 (34.6)
Severe	3 (5.8)
ND	8 (15.4)

BMI: Body mass index; TNF: Tumor necrosis factor; IFX: Infliximab; ADA: Adalimumab; CDAI: Crohn’s disease activity index; ND: No data.